Full Press Release Details
dupixent dupilumab sbla for treatment of eosinophilic esophagitis eoe in children aged 1 to 11 accepted for fda priority review.
REGN
dupixent dupilumab sbla for treatment of eosinophilic esophagitis eoe in children aged 1 to 11 accepted for fda priority review
Key Takeaway: dupixent dupilumab sbla for treatment of eosinophilic esophagitis eoe in children aged 1 to 11 accepted for fda priority review